Romark raises $23.1 million

TAMPA — Romark Laboratories raised $23.1 million in an equity offering, a filing with the Securities and Exchange Commission shows. Romark is a pharmaceutical company that develops molecular treatments for infectious diseases and cancers.

The offering attracted 155 investors, the filing shows. Romark paid $2.4 million, or 10% of gross proceeds plus $75,000, in commission on the offering, giving the company just over $20 million in net proceeds from the deal. Tampa-based GunnAllen Financial Inc. was one of three firms to receive sales compensation on the deal.

In April 2010, a Romark drug that treats Hepatitis-C succeeded in a clinical trial.